KK2260 / Kyowa Kirin - LARVOL DELTA

KK2260: A fully human tetravalent bispecific antibody targeting TfR1 and EGFR for the treatment of EGFR-expressing tumors (AACR 2024) - "KK2260 demonstrated potent anti-cancer effect both in vitro and in vivo. Intriguingly, KK2260 did not inhibit EGFR phosphorylation while EGFR-binding dependent TfR1 downregulation resulted in intracellular iron deficiency, which was considered as the MOA of KK2260. KK2260 was well tolerated in non-human primates."

Bispecific • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • EGFR • TFRC

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=169 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd. | Trial completion date: May 2029 ➔ Apr 2030 | Trial primary completion date: Nov 2028 ➔ Oct 2029

Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CRP

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=139 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd.

New P1 trial • Esophageal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CRP